EuroPCR 2019 | MeRes-1: Bioresorbable Scaffolds Return with Renewed Strength

A small number of highly selected patients presents good outcomes with new bioresorbable scaffold MeRes, but much more evidence is necessary to bring back the concept.

EuroPCR 2019 | CHOICE: válvula balón expandible vs autoexpandibles en pacientes de alto riesgo

The MeRes-1 study tested the newest generation of the Meril Life Sciences bioresorbable scaffold, a device featuring thinner struts compared with Absorb (from 150 µm in Absorb to only 100 µm). Results at 3 years are relatively good, with a major event rate of just 1.87%.

The study included 107 patients treated with the sirolimus-eluting scaffold and only two of them required revascularization of the target lesion.

Moreover, in the MeRes-1 Extend study, a similar trial with 62 patients, the 2-year major adverse cardiac events (MACE) rate was 1.61%, with just one case of ischemia-driven revascularization.


Read also: EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients.


Significantly, no cases of thrombosis were reported in any of these works.

The MeRes scaffold has already been approved in India and received CE Mark approval for Europe a few days ago.

These are promising data mainly regarding device safety in relatively simple lesions, but there is a need for further long-term evidence comparing device efficacy and safety with that of contemporary drug-eluting stents.

Original Title: MeRes-1 Extend: imaging and two-year clinical outcomes of thin-strut sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease.

Reference: Abizaid A.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...